Identity
- Security key
- 22142
- Ticker
- STOK
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2019-06-19
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- STOK
Detail
Enriched 2026-08-14 20:47
- Market cap
- $2,127,430,198.74
- Shares outstanding (class)
- 64,526,242
- Shares outstanding (weighted)
- 64,526,242
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 170
- Location
- BEDFORD, MA
- Description
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Market cap and share counts drift.